Printer Friendly

Study of Factors Influencing Dry Eye in Rheumatoid Arthritis.

1. Introduction

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease and characterized by joint synovitis and multiple symmetric small and large joint lesions. It is the most commonly observed type of inflammatory arthritis. The incidence of RA in the world and China is about 0.02% and 0.017%, respectively, and the prevalence is about 0.5-1% and 0.35-0.42%, respectively [1-5]. However, in some specific groups, such as the Pima Indians in North America, the incidence can be as high as 2-2.1% [6]. The proportion of women in RA patients is about 60-75%, which is 2-3 times of men, and the disease occurs between fourth and sixth decades of life [6, 7]. In general, the prevalence of RA goes on increasing with age; however, there is no sufficient evidence to suggest that the incidence changes with age. The severity of RA with age, disease activity, and extra-articular manifestations has decreased, which may be related to new treatments, drugs, and other factors [8-10]. In addition, the mortality of RA tends to decline over time [11] but still is higher compared with the general population [8].

RA is mainly considered as a joint disease, but it has the capacity to inflict multiple organs because of the abnormal systemic immune response. About 17.8-47.5% of patients present the extra-articular manifestations [12, 13], among which the ocular surface manifestation is the most common [14,15], which seriously affects the quality of life [16]. Earlier studies have shown that synovitis is the pathological basis for joint injury in RA [5]. Due to the complex interactions between the genes and environment, the immune tolerance is destroyed and synovitis gets presented in a typical symmetrical pattern [17]. In some cases, the rheumatoid factor (RF)--a group of autoantibodies that activate the complement pathways--can cause the extra-articular damage [18]. Most of these complications are pathologically based on pannus [5] and may occur in the skin, eyes, lungs, heart, kidneys, blood vessels, salivary glands, central and peripheral nervous systems, and bone marrow. The high mortality in RA is mainly associated with the extra-articular complications [12, 13, 18].

It has been reported that the incidence of dry eye in the general population is about 5-17% [19-22], while in the patients with RA, it is as high as 19-31% [23-28]. Recent studies show that the pathogenesis of dry eyes is similar to the other extra-articular complications of RA, which may be a mucosal autoimmune disease [29, 30]. It is speculated that the degree of dry eye may also change with the systemic conditions, due to the influence of systemic immune response. Therefore, this study intended to explore the following questions through the detection indicators of dry eyes in RA patients: (1) the relationship between dry eye and disease activity in patients with RA; (2) the difference in the extent of dry eye in RA patients with and without dry eye symptoms; (3) to find the correlation between the degree of dry eye and the course of disease.

2. Methods

2.1. Patients. A total of 30 adult RA patients (including 6 males and 24 females) were recruited from the Xiamen Eye Center, affiliated to the Xiamen University, between October 2016 and December 2018, which were selected on the following basis: (1) patients who came to the hospital for medical treatment; (2) community screening for cataract; (3) social recruitment using the Internet. All of the patients were previously diagnosed with positive or typical RA, thereby fulfilling at least 4 of 7 criteria as required by the American College of Rheumatology in 1988 [31].

Patients with previously known allergic conjunctivitis, any corneal lesions, chronic dacryocystitis, trachoma, blepharitis and other ocular surface diseases or primary or secondary Sjogren's syndrome, hyperthyroidism, diabetes, and other systemic diseases that can affect the tear secretion and tear film stability, were excluded. Also, the patients who had undergone an ocular surgery or who used worn contact lenses or any eye drops or visual display terminal for more than 4 hours per day were excluded.

Twenty healthy adults (including 4 males and 16 females) with matched sex and age were selected as the control group that included the cataract patients before surgery and the hospital staff.

2.2. Questionnaire. All the RA patients were graded by the Ocular Surface Disease Index (OSDI) questionnaire, a reliable and commonly used survey in the assessment of symptoms of ocular surface disease [32]. It consisted of 12 items that assessed the symptoms, functional limitation, and environmental factors related to dry eye [33], with an overall score of 0-100. The severity of ocular surface diseases assessed by OSDI was graded as follows: 0-12: normal; 13-22: mild; 23-32: moderate; 33-100: heavy [34]. Another survey used to assess the rheumatoid arthritis was the disease activity questionnaire (DAS-28) [35], which evaluated the number of tender and swollen joints (28-joints count), self-assessment of disease activity of the patients, and erythrocyte sedimentation rate (ESR) [36]. According to the OSDI, the patients were graded into the symptomatic group (score [greater than or equal to] 12) and the asymptomatic group (score < 12). According to the DAS-28 scores, they were graded into the active group (score > 2.6) and the stable group (score [less than or equal to] 2.6).

2.3. Measurement of Tear Film Break Time (TBUT). The ocular surface analyzer (Oculus keratography: SIRIUSANTARES (Italy C. S. O. SRL)) was used in the inspection of TBUT. The procedure involved is as follows: patients who were able to cooperate were asked to blink their eyes twice after the prior adjustment of the focal length, and then keep open, until the eyes automatically blinked or till the sampling procedure ended. Patients who faced difficulty to cooperate were asked to keep their eyes open with silent counting for 10 s at the beginning of the examination. The obtained test results were recorded for all the patients.

2.4. Measurement of Tear Meniscus Height (TMH). The ocular surface analyzer (Oculus keratography: SIRIUS-ANTARES (Italy C. S. O. SRL)) was used in the inspection of TMH. The procedure involved is as follows. The lower tear meniscus was focused and the hand putter was adjusted to make the focus clear. The acquisition button was quickly clicked to take the images. If the lacrimal stream of the patient was narrow and clear images could not be obtained under infrared light, the white light source was selected for collection. The ruler button on the interface was selected and pulled from the upper edge of the tear river to the lower edge for measuring the tear meniscus height. This value gave the height value of the tear river.

2.5. Meibomian Scan (MS). The ocular surface analyzer (Oculus keratography: SIRIUS-ANTARES (Italy C. S. O. SRL)) was used in this inspection. The procedure involved is as follows. The upper and lower palpebral conjunctiva was, respectively, exposed to the infrared meibomian gland imaging system to get a clear image of the morphology. The image of white stripes showed the meibomian gland, and the degree of lack of glands was scored as follows [37]:

0 = no loss (normal)

1 = gland deletion <1/3 of total area (mild)

2 = loss 1/3 to 2/3 (moderate)

3 = more than 2/3 loss (severe); the scores of upper and lower eyelids were added and scaled in the range 0-6

2.6. Corneal Fluorescein Staining (CFS). The slit-lamp microscope (SL990N (Italy C. S. O. SRL)) was employed in this inspection. A fluorescein paper was moistened with normal saline and subjected at the lower fornix of the patient. Patients were asked to close and open eyes for the proper distribution around the cornea. The number of dot stains obtained were observed under the cobalt blue light, and scores were assigned as follows: 0 = no stain; 1 point = 1~10 dot staining; 2 points = 10~30 dot staining; 3 points = point stain fusion, filaments, and ulcers.

2.7. Measurement of Meibomian Gland Secretion Score (MSS). After hot compression for 10 minutes, a digital pressure was applied to the tarsal plate by two cotton buds to squeeze the meibomian secretions, and the quality of the expressed lipid was observed and graded as follows [38]: 0 = clear fluid; 1 = cloudy fluid; 2 = cloudy particulate fluid; 3 = inspissated (like toothpaste).

2.8. Measurement of Eyelid Margin Assessment (EMS). A Slitlamp microscope (SL990N (Italy C. S. O. SRL)) was used for this study. The upper and lower eyelids were gently turned to expose the eyelid margin, and the following conditions were observed for their presence or absence: (1) the eyelid margin was hyperemic and round; (2) irregular eyelid margin; (3) blocked meibomian gland openings; (4) the skin mucosal boundary (Marx line) moved forward or backward. Scoring rules were as follows: 1 point or presence of each condition, 4 points in total; 0 for absence of all.

2.9. Statistical Analysis. Statistical analysis was performed using the SPSS 23.0 software; descriptive statistics methods were used for baseline characteristics (Mean [+ or -] SD). The Mann-Whitney U test was used to compare the discrete variables, and Spearman correlation test was computed to assess the dry eye and RA duration. The statistical significance was considered to be P < 0.05, and results were given with their 95% CIs.

3. Results

The control group (Con) and RA patients (RA): there were no significant differences in the age and sex between the two groups. TBUTof both the groups was significantly different and was significantly lower for the RA group (P = 0.001). The scores of MS, CFS, MSS, and EMS were significantly higher in the RA group than those of the normal (P [less than or equal to] 0.001), while there was no significant difference between both the groups for TMH (P = 0.331) (Figure 1; Table 1).

Symptomatic group (Sy) and asymptomatic group (Asy): according to the OSDI, there were 8 patients in the asymptomatic group and 22 patients in the symptomatic group, with no significant differences in the age and gender. Furthermore, there were no significant differences between the two groups in the TMH, MS, MSS, and EMS parameters (P > 0.05). The TBUT of the two groups was significantly different, and for the symptomatic group, it was significantly lower (P = 0.002). The CFS score was higher in the symptomatic RA group than in the asymptomatic RA group, and the difference was statistically significant (P = 0.001) (Figure 1).

Active group (Act) and stable group (Sta): A total of 18 patients in the active RA group and 12 patients in the stable RA group were found after evaluation using the DAS-28 questionnaire. There were no significant differences in the age and gender between the two groups. The CFS scoring showed a significant difference between the two groups, and for active group, it was significantly higher (P = 0.040) (Figure 1).

Duration (Dur) and dry eye (DE): the Spearman correlation test showed there was no correlation between the duration of the disease and the dry eye test items (P < 0.05) (Figure 2).

4. Discussion

The present study was aimed to explore the relationship between dry eye and the disease activity in patients with RA. The results of our study suggest that the patients with RA exhibited a shorter tear film breakup time, severe meibomian gland loss, degenerated blepharon lipids, severe corneal epithelial injury, and obvious changes in the blepharon morphology compared with the control group. Interestingly, there was no significant difference in the tear meniscus height between the two groups. The tear meniscus is an integral part of the tear film and the "repository" of tears. The amount of tears in the tear meniscus is about 75-90% of the total [39]. Although the measurement of tear meniscus height is one of the important indicators of the dry eye examination, it can merely reflect the level of tear secretion at that time. The mandatory open pattern required by the commonly used noninvasive ocular surface comprehensive analyzer may affect the measurement of lacrimal height due to the secretion of reflex tearing. Studies have found this condition even in the patients with aqueous tear deficiency [40]. Furthermore, in the patients with subjective dry eye symptoms, the reflex tear secretion was close to normal. The possible reasons for such results are speculated as follows: (1) RA patients are in the state of reflex tear secretion for a long time; hence, the tear secretion is maintained in the normal range; (2) RA patients may not have a reduced tear secretion, and the discomfort of subjective dry eye may be caused by other reasons.

The RA group exhibited higher CFS scores than those of the control group, and the dry eye symptoms group showed higher CFS scores than those of the asymptomatic group, with statistically significant differences. Lam et al. [41] reported that the level of cytokine interleukin--17 (IL--17) in tear was associated with the severity of the CFS. Lee et al. [42] showed that the corneal damage was caused by the excessive expression of proinflammatory cytokines of tear, and the epithelial damage due to the presence of cytokines of cell damage was severe than that due to the lack of water. In the RA patients with dry eye, the more heavily stained cornea indicated a more severe condition of the dry eye. Inflammatory cytokines may play an important role in the development of dry eye. Some scholars believe that, as the cornea is close to the palpebral conjunctiva and easily exposed to inflammatory cytokines expressed in the vessels, there is an increased chance of injury. However, the relationship between the tear components, including cytokines and dry eye, needs to be further explored.

There were significant differences between the RA group and the control group for TBUT and the meibomian gland examination. This suggests that the patients with RA may have varying degrees of meibomian gland dysfunction (MGD). The meibomian gland is the largest sebaceous gland in human body, and its main function is to secrete sebum and to form the outermost structure of tear film. The meibomian gland plays an important role in maintaining the stability of tear film. TBUT is currently a reliable indicator for assessing the tear film stability. Our results suggest that the TBUT of RA patients was shorter than that of the normal group and was shorter in the symptomatic RA group than that of the asymptomatic RA group. Thus, it can be concluded that the tear film stability is worse in RA patients, especially those with dry eye symptoms. It is speculated that the reason for poor tear film stability in RA patients may be caused by the abnormalities in the meibomian gland. There are many causes of MGD [43], which may be due to the attack of the immune system on one of the target organs, as in the case of Sjogren's syndrome [44].

The quality of tear film is closely related to the lipid layer formed by the sebum secreted by meibomian gland. Poor quality of the lipid layer not only affects the formation of tear film but also causes excessive evaporation of tears. Cornea protected by the tear film can be affected indirectly. Our results suggest that patients in the symptomatic group exhibited higher CFS scores, which means more spots were evident on the corneal epithelium. It was speculated that patients in the symptomatic group showed a more severe corneal damage.

The disease assessment of RA can not only compare the effects of treatment at different stages of individuals but also help to assess the progress of disease. According to the clinical observations, we expected that the disease activity might be positively correlated with dry eye and patients in the disease active stage might have more severe dry eye. However, our results suggested that there was no much significant difference between the active or stable groups, except for the CFS. We assumed that in the beginning of the active stage in RA, the patients may have more serious dry eye condition. However, our experimental results (Figure 1) suggested that the patients in stable stage of RA showed similar severity of dry eye to those in active group. Detailed dry eye examinations should be paid to all the RA patients, as patients in the stable stage exhibited mild dry eye. In addition, these results were consistent with the study of Miho Fujita et al. on the RA patients with nonsecondary Sjogren's syndrome [45]. Schargus et al. [46] found that the disease activity and tear osmotic pressure showed a positive correlation.

TBUT and TMH were used to evaluate the quantity and quality of the tears. Our results indicated that the RA disease activity could be possibly related to the secretion of tears and no obvious correlation existed for the tear stability, although the disease activity can still have an influence on the tear composition.

Our analysis of the disease course of RA and dry eye suggested that no significant correlation existed between them, although studies have found that patients with RA disease activity for long duration can influence all aspects of the quality of life [47]. Since the dry eye is a multifactor disease and has certain compensation, the influencing factors of dry eye may not be RA disease itself. Hence, influenced by age, gender, and other factors, even in short duration of disease, the degree of dry eye may be more severe.

To sum up, we found that patients with RA can have a meibomian gland dysfunction (MGD), but the functional and morphological differences with simple MGD need to be verified by further experiments. Besides, most studies showed that the dry eye in RA patients was due to the secondary Sjogren's syndrome, but our findings suggest that RA patients (without secondary Sjogren's syndrome) did not exhibit poor tear secretion. However, we cannot rule out the influence of the tear reflex, and further evaluation of lacrimal gland function needs to be understood.

Our study proposed the following three aspects. First, the RA disease activity may not necessarily worsen the dry eye symptoms. On the contrary, the patients in the period of the active disease cannot be ignored for the presence of dry eye, since patients with dry eye often lack the signs and symptoms. Hence, irrespective of the progression of the RA disease activity, the possibility of dry eye should be evaluated and clinical intervention can be taken if necessary. Secondly, when patients with RA complain about dry eye symptoms, it may indicate the damage to the corneal epithelium. For such patients, a better attention needs to be paid to the corneal epithelium, which should be carefully examined and dealt with in time. Finally, the duration of RA may exhibit no correlation with the severity of the dry eye. Patients with RA should get checked for the presence of dry eye, regardless of the duration of the disease. The evaluation of the dry eye should be based on the clinical manifestations and symptoms, combined with the objective examination indexes.

The advantages of this study lie in the consistency of the clinical methods and prospective recruitment of the RA patients. Clinical examinations were evaluated by a same physician in a standardized way. There were few shortcomings in this study. (1) This was a small sample study, which may face limitations in reflecting the actual situation. An increased sample size can prevent such shortcomings. (2) The examination and evaluation of dry eye were not comprehensive. For example, the composition changes of tear and the morphological and functional examination of meibomian gland were insufficient. (3) This study failed to consider whether the treatment drugs for RA such as hormones and immune-suppressants exhibited any effects on the dry eye. This deficiency can be minimized by making a comparison between the patients treated with such drugs and those not.

Data Availability

The detailed data of individual cases used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.


This study was funded by grants from the National Key R&D Program of China (2018YFA0107301), the National Natural Science Foundation of China (81770891, 81970771, 81870627, and 81900822), the Health Research Talent Training Program of Fujian PRC (2016-ZQN-90), the Huaxia Translational Medicine Fund for Young Scholars (2017-A-001 and 2017-A-002), the Xiamen Key Medical and Health Project (3502Z20191101 (to ND)), and the Zhenjiang Science Technology Planning Project (SH2019033).


[1] J. S. Smolen, D. Aletaha, and I. B. McInnes, "Rheumatoid arthritis," The Lancet, vol. 388, no. 10055, pp. 2023-2038, 2016.

[2] S. Jin, M. Li, Y. Fang et al., "Chinese Registry of rheumatoid arthritis (credit): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis," Arthritis Research & Therapy, vol. 19, no. 1, p. 251, 2017.

[3] L. C. See, C. F. Kuo, I. J. Chou, M. J. Chiou, and K. H. Yu, "Sexand age-specific incidence of autoimmune rheumatic diseases in the Chinese population: a Taiwan population-based study," Seminars in Arthritis and Rheumatism, vol. 43, no. 3, pp. 381-386, 2013.

[4] Y. Alamanos and A. Drosos, "Epidemiology of adult rheumatoid arthritis," Autoimmunity Reviews, vol. 4, no. 3, pp. 130-136, 2005.

[5] Y. Alamanos, P. V. Voulgari, and A. A. Drosos, "Incidence and prevalence of rheumatoid arthritis, based on the 1987 American college of rheumatology criteria: a systematic review," Seminars in Arthritis and Rheumatism, vol. 36, no. 3, pp. 182-188, 2006.

[6] G. S. Cooper and B. C. Stroehla, "The epidemiology of autoimmune diseases," Autoimmunity Reviews, vol. 2, no. 3, pp. 119-125, 2003.

[7] C. C. Whitacre, "Sex differences in autoimmune disease," Nature Immunology, vol. 2, no. 9, pp. 777-780, 2001.

[8] E. Minichiello, L. Semerano, and M.-C. Boissier, "Time trends in the incidence, prevalence, and severity of rheumatoid arthritis: a systematic literature review," Joint Bone Spine, vol. 83, no. 6, pp. 625-630, 2016.

[9] S. Jean, M. Hudson, P. Gamache et al., "Temporal trends in prevalence, incidence, and mortality for rheumatoid arthritis in Quebec, Canada: a population-based study," Clinical Rheumatology, vol. 36, no. 12, pp. 2667-2671, 2017.

[10] J. Van Den Hoek, L. D. Roorda, H. C. Boshuizen et al., "Trend in and predictors for cardiovascular mortality in patients with rheumatoid arthritis over a period of 15 years: a prospective cohort study," Clinical and Experimental Rheumatology, vol. 34, no. 5, pp. 813-819, 2016.

[11] S. Dadoun, N. Zeboulon-Ktorza, C. Combescure et al., "Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis," Joint Bone Spine, vol. 80, no. 1, pp. 29-33, 2013.

[12] M. Prete, V. Racanelli, L. Digiglio, A. Vacca, F. Dammacco, and F. Perosa, "Extra-articular manifestations of rheumatoid arthritis: an update," Autoimmunity Reviews, vol. 11, no. 2, pp. 123-131, 2011.

[13] M. C. Hochberg, S. S. Johnston, and A. K. John, "The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006," Current Medical Research and Opinion, vol. 24, no. 2, pp. 469-480, 2008.

[14] C. Turesson, R. L. McClelland, T. J. H. Christianson, and E. L. Matteson, "Multiple extra-articular manifestations are associated with poor survival in patients with rheumatoid arthritis," Annals of the Rheumatic Diseases, vol. 65, no. 11, pp. 1533-1534, 2006.

[15] A. P. Vignesh and R. Srinivasan, "Ocular manifestations of rheumatoid arthritis and their correlation with anti-cyclic citrullinated peptide antibodies," Clinical Ophthalmology, vol. 9, no. 9, pp. 393-397, 2015.

[16] R. O. Akintayo, O. O. Adelowo, O. Egajifo et al., "The impact of ocular manifestations of rheumatoid arthritis on the healthrelated quality of life and the functional ability of black Africans," International Ophthalmology, vol. 39, no. 5, 2018.

[17] O. Evren Kemer, "Dry eye in rheumatoid arthritis," International Ophthalmology Clinics, vol. 57, no. 2, pp. 89-99, 2017.

[18] S. Ruddy, E. D. Harris, C. B. Sledge, A. Editors, R. C. Budd, and J. S. Sergent, Kelley's Textbook of Rheumatology, Elsevier, Amsterdam, Netherlands, 2013.

[19] A. Millan, E. Viso, F. Gude, A. Parafita-Fernandez, N. Morana, and M. T. Rodriguez-Ares, "Incidence and risk factors of dry eye in a Spanish adult population," Cornea, vol. 37, no. 12, pp. 1527-1534, 2018.

[20] A. E. Osae, U. Gehlsen, J. Horstmann et al., "Epidemiology of dry eye disease in Africa: the sparse information, gaps and opportunities," The Ocular Surface, vol. 15, no. 2, pp. 159-168, 2017.

[21] T. Hikichi, A. Yoshida, Y. Fukui et al., "Prevalence of dry eye in Japanese eye centers," Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 233, no. 9, pp. 555-558, 1995.

[22] D. A. Schaumberg, R. Dana, J. E. Buring, and D. A. Sullivan, "Prevalence of dry eye disease among US men: estimates from the physicians' health studies," Archives of Ophthalmology, vol. 127, no. 6, pp. 763-768, 2009.

[23] I. Kotter, N. Stubiger, and C. Deuter, "Augenbeteiligung bei rheumatoider arthritis, kollagenosen und vaskulitiden," Zeitschrift fur Rheumatologie, vol. 76, no. 8, pp. 673-681,2017.

[24] C. Hart, M. Ferdinands, and L. Barnsley, "Ocular complications of rheumatic diseases," Medical Journal of Australia, vol. 206, no. 5, pp. 224-228, 2017.

[25] P. I. Murray and S. Rauz, "The eye and inflammatory rheumatic diseases: the eye and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis," Best Practice & Research Clinical Rheumatology, vol. 30, no. 5, pp. 802-825, 2016.

[26] E. Generali, L. Cantarini, and C. Selmi, "Ocular involvement in systemic autoimmune diseases," Clinical Reviews in Allergy & Immunology, vol. 49, no. 3, pp. 263-270, 2015.

[27] F. Hamideh and P. E. Prete, "Ophthalmologic manifestations of rheumatic diseases," Seminars in Arthritis and Rheumatism, vol. 30, no. 4, pp. 217-241, 2001.

[28] V. F. Baldassano Jr., "Ocular manifestations of rheumatic diseases," Current Opinion in Ophthalmology, vol. 9, no. 6, pp. 85-88, 1998.

[29] S. B. Brusca, S. B. Abramson, and J. U. Scher, "Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity," Current Opinion in Rheumatology, vol. 26, no. 1, pp. 101-107, 2014.

[30] M. E. Stern, C. S. Schaumburg, and S. C. Pflugfelder, "Dry eye as a mucosal autoimmune disease," International Reviews of Immunology, vol. 32, no. 1, pp. 19-41, 2013.

[31] F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., "The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis," Arthritis & Rheumatism, vol. 31, no. 3, pp. 315-324, 1988.

[32] R. M. Schiffman, M. D. Christianson, G. Jacobsen, J. D. Hirsch, and B. L. Reis, "Reliability and validity of the ocular surface disease index," Archives of Ophthalmology, vol. 118, no. 5, pp. 615-621, 2000.

[33] B. E. Dougherty, J. J. Nichols, and K. K. Nichols, "Rasch analysis of the ocular surface disease index (OSDI)," Investigative Opthalmology & Visual Science, vol. 52, no. 12, pp. 8630-8635, 2011.

[34] K. L. Miller, J. G. Walt, D. R. Mink et al., "Minimal clinically important difference for the ocular surface disease index," Archives of Ophthalmology, vol. 128, no. 1, pp. 94-101, 2010.

[35] M. L. L. Prevoo, H. Van'T, H. H. Kuper, M. A. Van Leeuwen, L. B. A. Van De Putte, and P. L. C. M. Van Riel, "Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis," Arthritis & Rheumatism, vol. 38, no. 1, pp. 44-48, 1995.

[36] I. B. Slama, F. Allali, T. Lakhdar et al., "Reliability and validity of CDAI and SDAI indices in comparison to DAS-28 index in Moroccan patients with rheumatoid arthritis," BMC Musculoskeletal Disorders, vol. 16, p. 268, 2015.

[37] R. Arita, K. Itoh, K. Inoue, and S. Amano, "Noncontact infrared meibography to document age-related changes of the meibomian glands in a normal population," Ophthalmology, vol. 115, no. 5, pp. 911-915, 2008.

[38] A. J. Bron, L. Benjamin, and G. R. Snibson, "Meibomian gland disease. Classification and grading of lid changes," Eye, vol. 5, no. 4, pp. 395-411, 1991.

[39] M. J. Doughty, M. Laiquzzaman, E. Oblak, and N. Button, "The tear (lacrimal) meniscus height in human eyes: a useful clinical measure or an unusable variable sign?" Contact Lens and Anterior Eye, vol. 25, no. 2, pp. 57-65, 2002.

[40] S. Koh, C. Ikeda, S. Watanabe et al., "Effect of non-invasive tear stability assessment on tear meniscus height," Acta Ophthalmologica, vol. 93, no. 2, pp. e135-e139, 2015.

[41] H. Lam, L. Bleiden, C. S. De Paiva, W. Farley, M. E. Stern, and S. C. Pflugfelder, "Tear cytokine profiles in dysfunctional tear syndrome," American Journal of Ophthalmology, vol. 147, no. 2, pp. 198-205, 2009.

[42] S.-Y. Lee, A. Petznick, and L. Tong, "Associations of systemic diseases, smoking and contact lens wear with severity of dry eye," Ophthalmic and Physiological Optics, vol. 32, no. 6, pp. 518-526, 2012.

[43] P. Chhadva, R. Goldhardt, and A. Galor, "Meibomian gland disease," Ophthalmology, vol. 124, no. 11, pp. S20-s26, 2017.

[44] Y. S. Kang, H. S. Lee, Y. Li, W. Choi, and K. C. Yoon, "Manifestation of meibomian gland dysfunction in patients with Sjogren's syndrome, non-Sjogren's dry eye, and non-dry eye controls," International Ophthalmology, vol. 38, no. 3, pp. 1161-1167, 2018.

[45] M. Fujita, T. Igarashi, T. Kurai, M. Sakane, S. Yoshino, and H. Takahashi, "Correlation between dry eye and rheumatoid arthritis activity," American Journal of Ophthalmology, vol. 140, no. 5, pp. 808-813, 2005.

[46] M. Schargus, F. Wolf, H.-P. Tony, T. Meyer-Ter-Vehn, and G. Geerling, "Correlation between tear film osmolarity, dry eye disease, and rheumatoid arthritis," Cornea, vol. 33, no. 12, pp. 1257-1261, 2014.

[47] Y. M. Chiu, M. S. Lai, H. Y. Lin, H. C. Lang, L. J. Lee, and J. D. Wang, "Disease activity affects all domains of quality of life in patients with rheumatoid arthritis and is modified by disease duration," Clinical and Experimental Rheumatology, vol. 32, no. 6, pp. 898-903, 2014.

Weifang Ma, (1,2) Guoliang Wang, (1,2) Xiaofeng Li, Huping Wu, Zuguo Liu, (1,2) NuoDong [ID], (1, 3) and Cheng Li [ID] (1,2)

(1) Eye Institute & Affiliated Xiamen Eye Center, School of Medicine, Xiamen University, Xiamen, China

(2) Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Xiamen, China

(3) Department of Ophthalmology, Affiliated People's Hospital & Zhenjiang Kangfu Eye Hospital, Jiangsu University, Zhenjiang, Jiangsu, China

Correspondence should be addressed to Nuo Dong; and Cheng Li;

Received 2 November 2019; Revised 23 April 2020; Accepted 11 May 2020; Published 8 August 2020

Academic Editor: Hong Liang

Caption: Figure 1: The Mann-whitney U test of every examined items in RA patients and control group (RA and Con), symptomatic group and asymptomatic group (sy and asy), and active group and stable group (act and sta). (***P < 0.001, **P < 0.01, and *P < 0.05).

Caption: Figure 2: Correlation between the duration of RA patients and each ocular tests. The P value was calculated by the spearman correlation test.
Table 1: Dry eye assessment and statistical results between each

                       RA                     Con              P

Mean age      51.933 [+ or -] 9.89   50.150 [+ or -] 9.433   0.463
Male/female           6/24                   4/16            0.533
TBUT (s)      5.267 [+ or -] 3.478   10.868 [+ or -] 1.816   0.001
TMH (mm)      0.186 [+ or -] 0.158   0.150 [+ or -] 0.052    0.331
MS            3.733 [+ or -] 1.710   1.250 [+ or -] 1.118    0.001
MSS           1.867 [+ or -] 0.834   0.400 [+ or -] 0.598    0.001
EMS           1.333 [+ or -] 0.900   0.300 [+ or -] 0.470    0.001
CFS           1.733 [+ or -] 0.961   0.150 [+ or -] 0.366    0.001

                        Ac                      Sta              P

Mean age      49.400 [+ or -] 10.762   57.000 [+ or -] 5.249   0.055
Male/female            4/14                    2/10            0.397
TBUT (s)       4.545 [+ or -] 2.066    6.710 [+ or -] 5.147    0.619
TMH (mm)       0.211 [+ or -] 0.184    0.137 [+ or -] 0.069    0.619
MS             3.800 [+ or -] 1.814    3.600 [+ or -] 1.673    0.746
MSS            2.000 [+ or -] 0.943    1.600 [+ or -] 0.548    0.307
EMS            1.200 [+ or -] 1.033    1.600 [+ or -] 0.548    0.267
CFS            2.100 [+ or -] 0.876    1.000 [+ or -] 0.707    0.04

                        Sy                      Asy              P

Mean age      50.454 [+ or -] 10.220   53.500 [+ or -] 7.270   0.730
Male/female            4/18                     2/6            0.534
TBUT (s)       3.918 [+ or -] 2.128    8.975 [+ or -] 3.886    0.002
TMH (mm)       0.177 [+ or -] 0.175    0.213 [+ or -] 0.099    0.097
MS             4.182 [+ or -] 1.471    2.500 [+ or -] 1.915    0.156
MSS            2.091 [+ or -] 0.831    1.250 [+ or -] 0.500    0.097
EMS            1.455 [+ or -] 0.934    1.250 [+ or -] 0.957    1.000
CFS            2.091 [+ or -] 0.831    0.750 [+ or -] 0.500    0.001

                R      P (Dur and RA)

Mean age
TBUT (s)      -0.119        0.532
TMH (mm)      0.341         0.066
MS            0.251         0.367
MSS           0.104         0.712
EMS           0.127         0.652
CFS           0.074         0.794

Data are shown as mean [+ or -] SD; Con: control group, RA: RA group,
act: active group, Sta: stable group, Sy: symptomatic group, Asy:
asymptomatic group, Dur: duration. The P value was calculated by
using the Mann-Whitney U test or the spearman correlation test.
R: coefficient of spearman correlation test.
COPYRIGHT 2020 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2020 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Ma, Weifang; Wang, Guoliang; Li, Xiaofeng; Wu, Huping; Liu, Zuguo; Dong, Nuo; Li, Cheng
Publication:Journal of Ophthalmology
Geographic Code:9CHIN
Date:Aug 31, 2020
Previous Article:Comparison of the Effect of Ranibizumab and Aflibercept on Changes in Macular Choroidal Thickness in Patients Treated for Diabetic Macular Edema.
Next Article:Evaluation of the Utility of Capsular Stabilization Devices in a Zonular Fiber Defect Model with the Slit Side View System.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |